Shopping Cart
Remove All
Your shopping cart is currently empty
TT-OAD2 free base has the potential for diabetes treatment. TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 100 mg | Inquiry | Inquiry | Inquiry | |
| 500 mg | Inquiry | Inquiry | Inquiry |
| Description | TT-OAD2 free base has the potential for diabetes treatment. TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. |
| Targets&IC50 | GLP1 receptor:(EC50)5 nM |
| In vitro | TT-OAD2, at concentrations ranging from 0 to 10 μM, suppresses GLP-1- and oxyntomodulin-induced responses—including cAMP, calcium, pERK1/2, and β-arrestin—in a dose-dependent manner within HEK293A cells. |
| In vivo | TT-OAD2 ?treatment induces plasma insulin in an acute IVGTT on humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice. |
| Molecular Weight | 856.83 |
| Formula | C50H47Cl2N3O6 |
| Cas No. | 1246826-07-2 |
| Smiles | [C@@H](CC)(N1[C@H](C(N[C@@H](CC2=CC=C(C=C2)C=3C(C)=C(C)N=CC3)C(O)=O)=O)CC=4C(C1)=CC5=C(C4)OC[C@@](O5)(C6=CC=C(OCC7=CC(Cl)=C(Cl)C=C7)C=C6)[H])C8=CC=CC=C8 |
| Relative Density. | 1.31g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.